USPTO serial 85510388
XIGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 24, 2013
- Examiner
- KLINE, MATTHEW
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with XIGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
1066 Epalinges, CH
1066 Epalinges, CH
1066 Epalinges, CH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
David A. Jackson
DAVID A JACKSON KLAUBER JACKSON LLC25 E SPRING VALLEY AVESTE 160MAYWOOD, NJ 07607 2154Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Food supplements for medical purposes; pharmaceutical, veterinary and sanitary preparations, namely, anti-inflammatory drugs, inhibitors of cell signalling, anti-cancer drugs, antiinfectives and anti-viral drugs; dietetic substances adapted for medical use, namely, food for babies; adjuvants for medical purposes; proteins for medical purposes; biological preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular and rheumatologic diseases; ferments for pharmaceutical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; hormones for medical purposes; medicinal infusions for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes, excluding anti-viral and HIV pharmaceutical preparations and substances | SECTION 8 - CANCELLED | — |
| 035 | Advertising; business management; business administration assistance; providing office functions, providing business analysis and research services | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services and research, namely, pharmaceutical research in particular drug discovery, and design, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; providing pharmaceutical analysis and research services, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; design and development of computer hardware and software | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Xigen S.A.
- Other trademarks owned by Xigen S.A.
- Other trademarks owned by Xigen S.A.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named XIGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 5, 2020 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 24, 2018 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 24, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 20, 2013 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Aug 20, 2013 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Aug 20, 2013 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Aug 6, 2013 | PAPER RECEIVED | — | |
| Jul 29, 2013 | PAPER RECEIVED | — | |
| Jun 7, 2013 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jan 3, 2013 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Dec 11, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 11, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 21, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 5, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 5, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 5, 2012 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Nov 5, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 5, 2012 | ALIE | ASSIGNED TO LIE | — |
| Oct 25, 2012 | PAPER RECEIVED | — | |
| Apr 18, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 18, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 18, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 11, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 11, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 10, 2012 | NWAP | NEW APPLICATION ENTERED | — |